This grant from the National Cancer Institute supports the discovery and development of novel natural products for cancer interception and prevention, emphasizing safe, nontoxic, and efficacious compounds. The UG3 phase focuses on selecting clinically relevant targets and developing assays for bioactivity and toxicity screening. The subsequent UH3 phase involves screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of screened agents. This phased initiative aims to advance potential cancer prevention strategies through thorough research. The closing date for applications is June 13, 2025.
Opportunity ID: 356614
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-25-013 |
| Funding Opportunity Title: | Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 01, 2024 |
| Last Updated Date: | Oct 01, 2024 |
| Original Closing Date for Applications: | Jun 13, 2025 |
| Current Closing Date for Applications: | Jun 13, 2025 |
| Archive Date: | Jul 19, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) County governments Private institutions of higher education Public and State controlled institutions of higher education Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-013.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 356614 Full Announcement-RFA-CA-25-013 -> RFA-CA-25-013-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288388 | May 13, 2025 | Jun 13, 2025 | View |
Package 1
Mandatory forms
356614 RR_SF424_5_0-5.0.pdf
356614 PHS398_CoverPageSupplement_5_0-5.0.pdf
356614 RR_OtherProjectInfo_1_4-1.4.pdf
356614 PerformanceSite_4_0-4.0.pdf
356614 RR_KeyPersonExpanded_4_0-4.0.pdf
356614 RR_Budget10_3_0-3.0.pdf
356614 PHS398_ResearchPlan_5_0-5.0.pdf
356614 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
356614 RR_SubawardBudget10_30_3_0-3.0.pdf
356614 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
